Clinical trials: Synucleinopathy
Parkinson Disease, Movement Disorders
Dyskinesia in Parkinson's Disease (Study P04501)
The purpose of the study is to assess the efficacy and safety of a range of doses of SCH 420814 (preladenant) when used together with a stable dose of L-dopa/dopa decarboxylase inhibitor to treat Parkinson's disease.
- Conditions
- Parkinson Disease, Movement Disorders, Central Nervous System Diseases, Neurodegenerative Diseases
- Trial name
- NCT00406029
- Testing
- Preladenant, L-dopa, Other Parkinson's Disease treatments
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.
- Trial name
- NCT01130493
- Testing
- IPX066, CLE
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 110 people
- Sponsor
- Impax Laboratories, LLC
Parkinson Disease
A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)
This is a two part study to compare the PK of preladenant administered to participants with CRI to the PK of preladenant administered to healthy participants.
- Trial name
- NCT01323855
- Testing
- Preladenant
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.
- Trial name
- NCT01106976
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Parkinson Disease
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease.
- Trial name
- NCT03971617
- Testing
- Hydrogen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stony Brook University
Parkinson Disease
Nintendo WII and Exercises at Rehabilitation of Individuals With Parkinson's Disease
Patients with Parkinson's disease present motor dysfunctions such as stiffness, tremor, postural instability and bradykinesia, which leads to alterations of balance, necessitating specialized physiotherapeutic treatment.
- Trial name
- NCT03235284
- Testing
- Exercises, Nintendo Wii, Exercises and Nintendo Wii
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- Federal University of Bahia
Parkinson Disease, Overactive Bladder
Mirabegron in Parkinson Disease and Impaired Cognition
There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile.
- Conditions
- Parkinson Disease, Overactive Bladder, Impaired Cognition
- Trial name
- MICT-PD (NCT02536976)
- Testing
- mirabegron
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- HealthPartners Institute
Orthostatic Hypotension, Idiopathic Parkinson Disease
Lundbeck TOMs Orthostatic Hypotension
Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure levels upon standing from a seated position, may affect approximately one in three patients with Parkinson's disease (PD).
- Trial name
- NCT04510922
- Testing
- Droxidopa 100 MG [Northera]
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Alberto Espay, MD, MSc
Parkinson Disease
LIFUP for Treatment of Motor Deficits in Parkinson's Disease
The study will test the feasibility of using Low Intensity Focused Ultrasound Pulsation (LIFUP) to treat motor symptoms in Parkinson's Disease (PD).
- Trial name
- LIFUP PD (NCT04593875)
- Testing
- Active LIFUP Treatment
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of California, Los Angeles
Parkinson's Disease
Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
The aging Veteran population, together with high exposure to Agent Orange or other herbicides during military service, has made diseases such as Parkinson's disease (PD), currently affecting more than 80,000 Veterans, a major…
- Trial name
- Gen-Ex (NCT03607695)
- Testing
- Gait training
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- VA Office of Research and Development
Parkinsons Disease
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
The purpose of this study is to see if the study drug, Mirabegron, is safe and effective in treating symptoms of Overactive Bladder in people with Parkinson's Disease.
- Trial name
- Maestro (NCT02092181)
- Testing
- Mirabegron
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Daniel Burdick, MD
Parkinson's Disease
Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease
Patient reported outcomes (PRO) have become an important endpoint assessed in clinical trials. It is important to understand the relationship between medication and patients' symptomatology, quality of life and well-being.
- Trial name
- ADEQUA (NCT02289729)
- Volunteers
- 62 people
- Sponsor
- AbbVie
Parkinson's Disease
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
- Trial name
- NCT00199381
- Testing
- Istradefylline
- Where
- United States
- Volunteers
- 504 people
- Sponsor
- Kyowa Kirin, Inc.
Parkinson's Disease, Off Episodes of Parkinson Disease
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
A cardiac safety study of an investigational drug to see how it affects the heart in people with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
- Trial name
- NCT03187301
- Testing
- APL-130277, Moxifloxacin
- Where
- 15 sites in United States, Italy
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Parkinson's Disease
Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).
- Trial name
- NCT04506073
- Testing
- Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mya Schiess
Parkinson Disease
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
This is a randomized, placebo-controlled, 3-period crossover, balanced, single-site, third party-blind study of preladenant (SCH 420814) in participants with Parkinson disease (PD) to be conducted in conformance with Good…
- Trial name
- NCT00845000
- Testing
- SCH 420814 10 mg, SCH 420814 100 mg, Levodopa
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Idiopathic Parkinson Disease
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
Phase 3, international, multicenter, open-label 12 month safety study.
- Trial name
- NCT03051607
- Testing
- Tozadenant
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Biotie Therapies Inc.
Parkinson Disease
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
To investigate the efficacy and the safety of ropinirole PR/XR tablets to ropinirole immediate release (IR) tablets with advanced Parkinson's disease in conjunction with L-dopa in a double-blind, parallel group comparison study.
- Trial name
- NCT00823836
- Testing
- ropinirole PR/XR, ropinirole IR
- Where
- 54 sites in Japan
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease, Neurogenic Orthostatic Hypotension in Parkinson's Disease
Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)
The purpose of the present study is to determine whether the use of an abdominal binder is effective in the non-pharmacological management of orthostatic hypotension in patients suffering from Parkinson's disease
- Trial name
- ABOHP (NCT01971008)
- Testing
- Elastic abdominal binder
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University Innsbruck
Parkinson's Disease
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.
- Trial name
- NCT02246374
- Testing
- ExAblate Transcranial System
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- InSightec